# Florida Hospital Cancer Institute

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/florida-hospital-cancer-institute/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 84 |
| Citations | 312,417 |
| City | Orlando |
| Country | US |
| Description | Florida Hospital Cancer Institute is a research organisation in Orlando, US. OpenAlex records 1,304 works and 312,417 citations for it. 243 researchers list it as their most recent affiliation. |
| Homepage | https://www.floridahospitalcancer.com/ |
| OpenAlex ID | https://openalex.org/I4210085997 |
| Region | Florida |
| Researchers | 243 |
| ROR ID | https://ror.org/00aqz8k66 |
| Type | healthcare |
| Works | 1,304 |

## University papers

- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)
- [Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial](https://scholariq.org/papers/atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced/)
- [Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-in-patients-with-brafv600e-positive-advanced-non-small-cell-lung/)
- [IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain](https://scholariq.org/papers/impower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and/)
- [Measuring the side effects of taxane therapy in oncology](https://scholariq.org/papers/measuring-the-side-effects-of-taxane-therapy-in-oncology/)
- [Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pooled-analysis-of-cns-response-to-alectinib-in-two-studies-of-pretreated/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.